Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Euronext Paris  >  DBV Technologies    DBV   FR0010417345

DBV TECHNOLOGIES (DBV)
Mes dernières consult.
Most popular
Report
 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Euronext Paris
12/11/2017 12/12/2017 12/13/2017 12/14/2017 12/15/2017 Date
36.5(c) 36.25(c) 35.755(c) 36.415(c) 36.425(c) Last
74 105 98 876 97 739 98 490 57 812 Volume
0.00% -0.68% -1.37% +1.85% +0.03% Change
More quotes
Financials (€)
Sales 2017 14,0 M
EBIT 2017 -134 M
Net income 2017 -137 M
Finance 2017 119 M
Yield 2017 -
Sales 2018 17,0 M
EBIT 2018 -177 M
Net income 2018 -189 M
Finance 2018 46,5 M
Yield 2018 -
P/E ratio 2017 -
P/E ratio 2018
EV / Sales2017 56,3x
EV / Sales2018 50,8x
Capitalization 910 M
More Financials
Company
DBV Technologies SA is a clinical-stage biopharmaceutical company, which deals with conducting of research and development of epicutaneous immunotherapy products.The company focuses on developing a novel technology platform called Viaskin, which is an electrostatic patch that offers a convenient,... 
Sector
Pharmaceuticals
Calendar
03/05Earnings Release
More about the company
Surperformance© ratings of DBV Technologies
Trading Rating : Investor Rating :
More Ratings
Latest news on DBV TECHNOLOGIES
12/04 DBV TECHNOLOGIES : CEO, Chairman, and Co-Founder, Dr. Pierre-Henri Benhamou Reco..
11/28 DBV TECHNOLOGIES : to Attend Citi's 2017 Global Healthcare Conference
11/28 DBV TECHNOLOGIES : to Attend Citi's 2017 Global Healthcare Conference
11/20 DBV TECHNOLOGIES : Announces Positive Topline Safety Results from REALISE Phase ..
11/15 DBV TECHNOLOGIES : Announces Publication of Positive Data from Phase IIb Trial a..
11/14 DBV TECHNOLOGIES : Announces Publication of Positive Data from Phase IIb Trial a..
10/31 DBV TECHNOLOGIES : Reports September 30, 2017 Cash Position
10/31 DBV TECHNOLOGIES : Reports September 30, 2017 Cash Position
10/23 DBV TECHNOLOGIES : Announces Topline Results of Phase III Clinical Trial in Pean..
10/20 DBV TECHNOLOGIES : Announces Topline Results of Phase III Clinical Trial in Pean..
More news
Sector news : Diagnostic & Testing Substances Manufacturers
12/17 TEVA PHARMACEUTICAL INDUSTRIES : Strike over Teva Pharm job cuts briefly shuts d..
12/16 PROCTER & GAMBLE : P&G appoints Peltz to board despite losing proxy battle
12/16 NELSON PELTZ : P&G appoints Peltz to board despite losing proxy battle
12/15 JAZZ PHARMACEUTICALS : Pennsylvania man admits to trading on tips about drug com..
12/15DJSTOCKS TO WATCH : CSX, Aclaris, Alnylam, Rigel
More sector news : Diagnostic & Testing Substances Manufacturers
News from SeekingAlpha
12/07 AIMMUNE THERAPEUTICS : Upside Into Q1 Data And Beyond
12/06 DBV Technologies S.A. (DBVT) Presents At Citi Global Healthcare Conference - ..
11/30 PEANUT WARS : Things Are Heating Up Between Aimmune Therapeutics And DBV Technol..
11/29 Update On Aimmune Therapeutics Vs. DBV Technologies Peanut Allergy-Related Ca..
11/21 BIOTECH FORUM DAILY DIGEST : What Now For Sarepta?
Chart DBV TECHNOLOGIES
Duration : Period :
DBV Technologies Technical Analysis Chart | DBV | FR0010417345 | 4-Traders
Technical analysis trends DBV TECHNOLOGIES
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 7
Average target price 78,0 €
Spread / Average Target 114%
EPS Revisions
Managers
NameTitle
Pierre-Henri Benhamou Chairman & Chief Executive Officer
David S. Schilansky Chief Operating & Financial Officer
Bertrand Dupont Chief Technology Officer
Lucia Septién Chief Medical Officer
Hugh A. Sampson Chief Scientific Officer
Sector and Competitors
1st jan.Capitalization (M$)
DBV TECHNOLOGIES-45.10%1 069
JOHNSON & JOHNSON22.95%382 722
PFIZER12.25%221 738
NOVARTIS13.09%221 731
ROCHE HOLDING LTD.3.91%212 270
ABBVIE53.78%155 345